Pharma discovery platform built through deals

SmithKline Beecham has added two new pieces to its growing drug discovery platform, last week signing collaborations with Cadus Pharmaceutical Corp. in functional genomics and Evotec BioSystems GmbH in high throughput screening.

"About four years ago we identified four primary technologies as a critical base for drug discovery: genomics, bioinformatics, combinatorial chemistry and ultra-high throughput screening," said John Keller, director of the alliance and technology group at SmithKline.

The pharma company has built those capabilities through internal and external investments in genomics,

Read the full 806 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE